LOGIN  |  REGISTER
Recursion

Latest Peer Review News

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

July 9
Last Trade: 38.36 2.80 7.87

The previously disclosed and now published RESILIENT data show that once-nightly TNX-102 SL achieved statistically significant improvement in the primary endpoint of reducing fibromyalgia pain versus placebo, and was generally well tolerated These results confirm findings from the previously published RELIEF phase 3 trial, which also demonstrated a statistically significant reduction in fibromyalgia pain FDA target PDUFA date for...Read more


Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

July 9
Last Trade: 0.76 -0.03 -4.30

Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later this year Company continues to advance its contemplated merger with Decoy Therapeutics HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that two animal studies recently published in peer-reviewed journals provide additional insight into...Read more


New Clinical Findings Published in Scientific Journal Nature Validate LIXTE Biotechnology’s Ongoing Ovarian and Colorectal Cancer Trials

July 9
Last Trade: 2.75 0.22 8.70

Article Indicates that Inhibition of PP2A Enhances Immunotherapy Response with LIXTE’s Proprietary Compound LB100 PASADENA, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that the medical journal Nature has published findings by a team of physician-scientists that validate LIXTE’s ongoing...Read more


BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

July 8
Last Trade: 0.42 -0.01 -2.33

Premier research journal article provides validation for BiomX’s phage therapy platform, showcasing first-in-human Phase 1b/2a trial results for antibiotic-resistant P. aeruginosa infections New, updated data demonstrates a further bacteria reduction of 2.7 log₁₀ (approximately 500-fold) compared to placebo, with no emergent resistance and preservation of a healthy microbiome BiomX is advancing its Phase 2b trial of BX004 with topline...Read more


Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia

July 8
Last Trade: 3.46 0.14 4.22

Nonclinical findings provide evidence of the mechanism of action of nomlabofusp and support the potential use of skin FXN concentrations as a novel surrogate endpoint for Larimar’s planned BLA submission in Q2 2026 seeking accelerated approval BALA CYNWYD, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...Read more


Caris Life Sciences Announces New Study Demonstrating the Power and Clinical Utility of its Caris Assure® Blood-Based Assay for Multi-Cancer Early Detection, Minimal Residual Disease and Therapy Selection

July 8
Last Trade: 27.24 0.95 3.61

Scientific Reports study validates the first multifunctional, AI-enabled blood-based assay to offer diagnostic, prognostic and predictive utility in a single assay. IRVING, Texas, July 8, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced a landmark study published in Scientific Reports, a Nature...Read more


BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

July 7
Last Trade: 2.31 0.10 4.52

In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rate (ORR) of 23% and a disease control rate (DCR) of 54% in non-irradiated lesions. Biomarker analysis linked Plinabulin’s mechanism to GEF-H1–dependent dendritic cell maturation, offering the potential to pre-select patients at baseline and predict clinical response. FLORHAM...Read more


Cyclacel Pharmaceuticals Highlights Publication Of Preclinical Data Showing That Plogosertib Is Active In A Hard-to-Treat Subtype Of Liver Cancer

July 7
Last Trade: 3.73 0.37 11.01

Fibrolamellar hepatocellular carcinoma (FLC) has no approved treatment and occurs mostly in adolescents and young adults  KUALA LUMPUR, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative cancer medicines, highlighted a publication from independent investigators titled, “DNAJ-PKAc fusion...Read more


Monte Rosa Therapeutics Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

July 3
Last Trade: 5.29 0.23 4.55

Monte Rosa’s AI/ML-powered insights dramatically increase targetable protein space for molecular glue degraders, unlocking new opportunities to address previously undruggable therapeutic targets BOSTON, July 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the publication of groundbreaking...Read more


Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

July 2
Last Trade: 38.36 2.80 7.87

Combination treatment of mTNX-1700 (mTFF2-MSA fusion protein) with anti-PD1 antibody was associated with increased survival and decreased metastases in animal models of gastric cancer relative to anti-PD1 treatment alone mTNX-1700 treatment was associated with activation of cancer-killing CD8+ T Cells and limiting neutrophil-mediated immune evasion TNX-1700 (hTFF2-HSA fusion protein) is in preclinical development for gastric and...Read more


First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology

July 1
Last Trade: 2.21 0.02 0.91

ST. LOUIS, July 01, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publication of initial clinical results using the MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. Titled “First In‑Human Results of the MAGiC Robotic Magnetic Navigation Radiofrequency Ablation Catheter,” the publication is...Read more


New Evidence Supports the Value of Elutia’s Antibiotic-Eluting Platform for Implantable Devices

July 1
Last Trade: 2.52 0.25 10.79

The EluPro BioEnvelope findings demonstrate the bioactive properties and superior healing response compared to synthetic materials for cardiac implantable electronic devices (CIEDs)  GAITHERSBURG, Md., July 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of a new study describing the bioinductive effects of its...Read more


Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

June 30
Last Trade: 4.81 0.10 2.12

FRAME study demonstrated a 42.3% ORR and 20.1 months median PFS for all patients with low-grade serous ovarian cancer (LGSOC), regardless of KRAS mutation; for patients with KRAS-mutated LGSOC, ORR and mPFS were 58.3% and 30.8 months, respectively Study conducted by the Institute of Cancer Research and The Royal Marsden NHS Foundation Trust demonstrated the importance of the intermittent dosing schedule of the combination of avutometinib...Read more


I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

June 30
Last Trade: 2.31 0.11 5.00

Monotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy ROCKVILLE, MD, June 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of the first-in-human monotherapy data for...Read more


Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

June 30
Last Trade: 14.37 0.43 3.08

The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension Lorundrostat 50 mg once daily demonstrated clinically meaningful reductions in systolic blood pressure, with a 16.9 mmHg reduction at Week 6 and a 19.0 mmHg reduction at Week 12 Lorundrostat was generally well-tolerated; and treatment-emergent adverse events were mostly mild,...Read more


Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

June 30
Last Trade: 2.58 0.08 3.20

Compelling PAX-D results guided Alto’s acquisition of ALTO-207, designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole  Alto plans to collaborate with National Health Service, PAX-D clinical sites for the planned Phase 2b trial of ALTO-207, designed to be a potentially pivotal study; trial expected to initiate by mid-2026  MOUNTAIN VIEW, Calif. / Jun 30, 2025 / Business...Read more


New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

June 26
Last Trade: 6.00 0.88 17.19

Important Study Shows Vivos Technology to be a Safe and Highly Effective, Non-Surgical Alternative to Surgical Removal of Tonsils and Adenoids in Children LITTLETON, Colo., June 26, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced that the European Journal of Pediatrics has published the...Read more


Tempus AI: Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing

June 25
Last Trade: 58.41 -0.10 -0.17

Peer-reviewed study in the Journal of the National Comprehensive Cancer Network describes the CARE program’s utility as digital risk assessment tool validated with real-world patient data ALISO VIEJO, Calif. / Jun 25, 2025 / Business Wire / Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) company and a leader in clinical genomic testing, announced today that a peer-reviewed study validating the accuracy of...Read more


GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients in The Journal of Pediatrics

June 25
Last Trade: 91.88 6.66 7.82

Data demonstrates that rapid genomic testing dropped the average time to a precise genetic diagnosis from almost ten months to 13 days Despite broad utilization in the study, rapid genomic sequencing in non-critical care inpatients yielded a diagnostic rate over 42%, comparable to critical care settings Study supports broader adoption of rapid genomic testing in the non-critical care inpatient setting to improve pediatric patient...Read more


Oncotelic Therapeutics Announces Publication of Landmark Study on TGFB2 Gene Methylation as a Positive Prognostic Marker in Pancreatic Cancer

June 25
Last Trade: 0.05 0.00 0.00

AGOURA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical-stage biopharmaceutical company focused on RNA-based therapeutics, today announced the publication of a peer-reviewed research article highlighting TGFB2 gene methylation as a positive prognostic biomarker for pancreatic ductal adenocarcinoma (PDAC). The paper, published in collaboration with Sapu...Read more


CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure

June 25
Last Trade: 1.61 0.02 1.26

Publication includes previously announced preclinical data of Auxora™ in acute kidney injury (AKI) models as well as a post-hoc analysis of patients in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia who had AKI with respiratory failure at enrollment LA JOLLA, Calif., June 25, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on...Read more


Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence

June 25
Last Trade: 1.06 0.13 13.61

9.2% of Patients in REASSURE’s Primary Population had a Baseline Pathogen Resistant to Three or More Classes of Antibiotics DUBLIN and CHICAGO, June 25, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported...Read more


Abeona Therapeutics Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

June 24
Last Trade: 5.83 -0.01 -0.17

RDEB is a lifelong debilitating, blistering skin disease associated with large and painful wounds that often remain open for years and cause significant clinical burden, including pain, itch, and risk of squamous cell carcinoma  ZEVASKYN™ (prademagene zamikeracel) demonstrated significant wound healing and pain reduction after a single treatment with a favorable safety profile in large chronic RDEB wounds  ZEVASKYN is the...Read more


Corcept Therapeutics Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care

June 23
Last Trade: 70.89 2.72 3.99

Treatment with a cortisol modulator significantly improves glucose control in patients with hypercortisolism and difficult-to-control diabetes, accompanied by reductions in body weight, waist circumference and glucose-lowering medications CATALYST’s prevalence phase identified hypercortisolism in 24 percent of patients with difficult-to-control type 2 diabetes REDWOOD CITY, Calif. / Jun 23, 2025 / Business Wire / Corcept Therapeutics...Read more


Novo Nordisk: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

June 22
Last Trade: 69.67 0.03 0.04

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss interventions1 When adhering to treatment, weight loss of ≥5%, ≥20%, ≥25%, and ≥30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks1* The REDEFINE clinical programme is ongoing to further investigate...Read more


MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

June 18
Last Trade: 1.13 0.00 0.00

MIAMI, FL / ACCESS Newswire / June 18, 2025 / MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that the first manuscript describing its lead drug candidate Ketamir-2, currently being evaluated in an ongoing Phase 1 clinical trial for neuropathic pain, has been accepted for...Read more


Acurx Pharmaceuticals Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

June 17
Last Trade: 0.50 0.01 2.35

As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free of C. difficile infection (CDI) recurrence through one month after EOT In contrast, 2 of 14 (14%) patients treated with the standard of care, oral vancomycin, experienced recurrent infection within one month after EOT When Phase 2b results are combined with...Read more


Windtree Therapeutics Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study

June 16
Last Trade: 0.68 -0.11 -14.07

The Phase 2 Istaroxime study was successful in multiple endpoints showing promise for how it may be utilized if approved in its targeted indications    Primary endpoint of the study was met of increasing systolic blood pressure and demonstration of other benefits including no increase in heart rate and preserved renal function Partnership discussions with multiple potential partners that may fund the remainder of...Read more


Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

June 16
Last Trade: 11.22 0.36 3.31

Three Phase 1 studies support once-daily inhaled administration of mosliciguat with no evidence of serious systemic side effects Results informed the ongoing Phase 2 PHocus study of mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company dedicated to developing innovative therapies to...Read more


Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

June 12
Last Trade: 68.72 1.03 1.52

POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival...Read more


VolitionRx Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

June 12
Last Trade: 0.66 -0.04 -6.33

Peer Reviewed Clinical Study for H3.1 Biomarker Published in Critical Care HENDERSON, Nev., June 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the publication of a new clinical manuscript suggesting that the Nu.Q® H3.1 biomarker has the potential to inform clinical care in critically-ill Intensive Care Unit (ICU) patients in the assessment...Read more


NetraMark Founder Coauthors New Publication on AI/ML Use in Clinical Trials, Alongside Authors From Leading Global Regulatory Organizations

June 12
Last Trade: 1.23 -0.06 -4.65

TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) solutions company transforming clinical trial design in the pharmaceutical industry through streamlined access to actionable analytics uncovered by AI, today announced that NetraMark founder Dr. Joseph Geraci was the lead author on a new publication that outlines the...Read more


Teleflex: New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients

June 12
Last Trade: 118.93 -0.73 -0.61

WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guinea, Colombia,...Read more


Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)

June 11
Last Trade: 9.52 2.69 39.39

SYDNEY, June 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics, today announced the publication of transformative preclinical research in the journal Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research that underscores the powerful potential of its lead asset, paxalisib, in reshaping the treatment...Read more


New Study Finds Masimo SedLine® Brain Function Monitoring Offers Significant Advantages During Pediatric Anesthesia

June 10
Last Trade: 165.41 3.06 1.88

EEG-Guided Anesthesia Using Masimo Technology Significantly Reduced Pediatric Anesthesia Emergence Delirium, Time to Emergence and Discharge, and Cost of Care by Minimizing Sevoflurane Exposure NEUCHATEL, Switzerland / Jun 10, 2025 / Business Wire / Masimo (NASDAQ: MASI) today announced the findings of a randomized clinical trial published in JAMA Pediatrics in which Dr. Yasuko Nagasaka and colleagues at Tokyo Women’s Medical...Read more


Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

June 9
Last Trade: 7.83 0.00 0.00

Results demonstrated that nicotinamide riboside (NR) significantly elevated NAD+ levels and improved multiple clinical markers in people with Werner Syndrome Niagen Bioscience expands rare disease research portfolio, supporting further investigation of NAD+ augmentation with NR as a therapeutic strategy in rare progeroid diseases LOS ANGELES / Jun 09, 2025 / Business Wire / Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex...Read more


New Study Published in ESMO Open Highlights Guardant Health Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer

June 9
Last Trade: 51.04 0.22 0.43

LIBERATE Study: Guardant Reveal showed high sensitivity and 100% positive predictive value for relapse PALO ALTO, Calif. / Jun 09, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced results from the LIBERATE study published in ESMO Open. The results in the peer-reviewed manuscript demonstrate the clinical validity and high performance of Guardant Reveal, the company’s...Read more


AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™

June 5
Last Trade: 5.63 0.03 0.54

VALENCIA, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the first clinical publication evaluating Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix, published in the Journal of Surgery (Akpunonu et al., 2025). According to the investigators, Cohealyx demonstrated significantly faster...Read more


Scilex Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

June 5
Last Trade: 6.40 0.07 1.11

PALO ALTO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced a publication on GLOPERBA® dosing adjustments in peer-review journal. GLOPERBA® is...Read more


Biomerica’s inFoods® IBS Clinical Study Results Published in June Issue of Gastroenterology

June 5
Last Trade: 3.37 0.10 2.91

Landmark Peer-Reviewed Study Demonstrates Effectiveness of Personalized Dietary Therapy for IBS Patients Using inFoods® IBS Test. Gastroenterology, the premier journal in gastrointestinal science, features data supporting inFoods IBS as an effective personalized, non-drug approach for managing IBS. Study results suggest inFoods IBS could be particularly beneficial for IBS-M patients, a population with no current FDA-approved drug...Read more


LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

June 5
Last Trade: 47.17 0.51 1.09

This is the latest prospective evaluation of VNS Therapy in generalized tonic-clonic seizures Findings include 77% median seizure reduction and 43% of participants reporting seizure freedom at 24-month visits LONDON / Jun 05, 2025 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant...Read more


Akebia Therapeutics: Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

June 4
Last Trade: 4.02 0.31 8.36

Akebia continues to publish important, clinically relevant data to further physicians’ understanding of Vafseo® (vadadustat) CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Journal of the American Society of Nephrology (JASN) has published pre-specified analyses...Read more


QHSLab Publishes Peer-Reviewed Studies Validating Digital Tools for Enhancing Patient Outcomes and Healthcare Efficiency

June 3
Last Trade: 0.22 0.00 0.00

Recent publications highlight the efficacy of QHSLab's digital assessments in primary care, offering benefits for providers, patients, and practice revenue.  WEST PALM BEACH, FL, June 03, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a digital health company advancing personalized medicine through innovative population health screening and point of care diagnostic tools in primary care, announces the...Read more


Amicus Therapeutics: New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

June 3
Last Trade: 6.42 0.20 3.22

PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) in Muscle and Nerve. In this new publication, based on a within group effect-size analysis, subjects who switched from alglucosidase alfa to...Read more


Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

June 3
Last Trade: 1.55 0.00 0.00

NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the publication of key clinical efficacy data for rigosertib, a legacy Traws Pharma oncology asset for which development and commercialization partners...Read more


Iovance Biotherapeutics: The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma

June 2
Last Trade: 1.99 0.22 12.43

One-time Amtagvi Treatment Continues to Show Deep, Durable Responses and Meaningful Survival One Third of Responses Remain Ongoing without Subsequent Treatment after Five Years Simultaneous Presentation at ASCO 2025 SAN CARLOS, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...Read more


New Independent Review Paper Strengthens Therapeutic Rationale for Artelo Biosciences’ FABP Inhibitor Program in Anxiety and Depression

June 2
Last Trade: 21.09 5.19 32.64

SOLANA BEACH, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today welcomed the publication of a comprehensive review in Neurobiology of Disease, titled “Fatty acid binding proteins and their involvement in anxiety...Read more


Amgen: IMDELLTRA Significantly Reduced Risk Of Death By 40% In Small Cell Lung Cancer Patients

June 2
Last Trade: 296.52 -0.48 -0.16

Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy  Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New England Journal of Medicine THOUSAND OAKS, Calif., June 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by...Read more


Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology

June 2
Last Trade: 2.12 0.23 12.17

Highlights the unique potential of Celularity’s proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstruction Supports broad range of regenerative medicine applications beyond ophthalmology FLORHAM PARK, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced its research...Read more


Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method

May 28
Last Trade: 2.52 0.25 10.79

Innovative approach accelerates new product development and testing  SILVER SPRING, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of a peer-reviewed article describing the first validated method for measuring antibiotic release from a biologic envelope. The novel method demonstrates in vitro elution...Read more


Cumberland Pharmaceuticals: New Study Finds Caldolor Safe And Effective For Opioid-Sparing Pain Management In Older Adults

May 27
Last Trade: 3.09 0.02 0.49

Analysis Shows 23% Reduction in Morphine Use with Favorable Safety Profile in Patients 60 Years of Age and Older NASHVILLE, Tenn., May 27, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced the publication of its study investigating Caldolor® (intravenous ibuprofen) in older patients. The analysis evaluated the safety and efficacy of Caldolor for the...Read more


Spectral AI: DeepView System Achieves 95.3% Accuracy Evaluation as Published in Burns Journal

May 27
Last Trade: 3.14 0.30 10.56

DALLAS, May 27, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ: MDAI) (“Spectral AI” or the “Company”), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential today announced that the Company’s DeepView System has been featured in the journal Burns as part of a clinical study in which it achieved a 95.3% overall accuracy assessment as compared to...Read more


Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2...

May 27
Last Trade: 0.75 0.03 4.34

CANOPY assessed pemivibart safety and tolerability, antiviral immunobridging, and exploratory efficacy against COVID-19, and is the only clinical trial of an authorized or approved COVID-19 monoclonal antibody or vaccine with placebo-controlled clinical efficacy data in a contemporary, seropositive U.S. population and facing modern, immune-evasive SARS-CoV-2 viruses Pemivibart demonstrated strong protection from symptomatic COVID-19...Read more


Tempus AI: New Study Shows Impact of Ambry Genetics’ Patient for Life™ Program on Rare Disease Diagnosis

May 27
Last Trade: 58.41 -0.10 -0.17

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes ALISO VIEJO, Calif. / May 27, 2025 / Business Wire / Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), and a leader in clinical genomic testing, today announced the publication of a study in Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG). The study...Read more


Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System

May 22
Last Trade: 3.37 0.10 2.91

Real-World Impact: Initial data from over 360 patients shows inFoods® IBS delivered an average 48.5% reduction in gastrointestinal pain and a 49.8% reduction in bloating over an 8-week period First-of-Its-Kind inFoods® IBS Feedback Platform: New real-time feedback system empowers physicians to adjust patient treatment based on actionable, patient-reported outcomes Precision Medicine: inFoods® IBS identifies specific individual food...Read more


GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale

May 22
Last Trade: 91.88 6.66 7.82

Company deploying AI to scale industry-leading rare disease dataset to diagnose growing number of patients with genetic disease, published in the American Journal of Medical Genetics GAITHERSBURG, Md. / May 22, 2025 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the publication of a new article in the American Journal of Medical Genetics, demonstrating...Read more


Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

May 22
Last Trade: 9.66 0.40 4.32

Data showed that both Evolysse™ Form and Evolysse™ Smooth met the primary endpoint of non-inferiority1 and demonstrated statistical superiority1 to Restylane®-L, the control product The study published in Aesthetic Surgery Journal supports long-term safety and effectiveness of Cold-X™ crosslinked injectable hyaluronic acid (HA) gels for the correction of dynamic facial wrinkles and folds NEWPORT BEACH, Calif. / May 22, 2025 / Business...Read more


Becton Dickinson: Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs'

May 21
Last Trade: 175.50 0.87 0.50

FRANKLIN LAKES, N.J., May 21, 2025 /PRNewswire/ -- First-of-their-kind studies published in The Lancet Oncology1 and Cancer Medicine2 provide new data showing that cancer patients in both hospital and outpatient settings are at a substantially higher risk of developing antimicrobial resistant (AMR) infections compared to all other non-cancer patients. Key Takeaways: The studies, led by the Cancer and AMR Consortium, which...Read more


ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases

May 20
Last Trade: 0.66 -0.12 -15.10

Study results corroborate our recently published data demonstrating the critical role of microglial-driven inflammation in promoting accumulation and spread of toxic phosphorylated alpha-synuclein leading to neurodegeneration in Parkinson’s Disease (PD). Our data showed that microglial inflammation was driven by activation of NLRP1 inflammasomes triggered by ASC specks and alpha-synuclein aggregates. Inflammasome ASC Inhibitor IC 100...Read more


BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology

May 20
Last Trade: 0.33 -0.01 -2.94

Novel Graph Neural Network (N-GNN) Model Achieves Superior Accuracy in Early Lung Cancer Detection, Paving the Way for Enhanced Diagnostic Capabilities. Vancouver, British Columbia--(Newsfile Corp. - May 20, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leader in developing liquid biopsy tests for early cancer detection, today announced the publication of a significant study exploring an...Read more


VolitionRx Announces Successful Detection of Nucleosomes in Cats

May 19
Last Trade: 0.66 -0.04 -6.33

Clinical Paper Published in BMC Veterinary Research HENDERSON, Nev., May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the publication of "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" in BMC Veterinary Research. This is the first study to report the detection of nucleosomes in cats:...Read more


Aldevron and Integrated DNA Technologies Manufacture World’s First mRNA-based Personalized CRISPR Therapy

May 15
Last Trade: 200.96 0.28 0.14

N of 1 therapy uniquely developed, on demand, for infant with life-threatening rare metabolic disorder in six months Results published in The New England Journal of Medicine and showcased at American Society of Gene & Cell Therapy Annual Meeting FARGO, N.D. & CORALVILLE, Iowa / May 15, 2025 / Business Wire / Aldevron, a global leader in the production of DNA, RNA and protein, together with Integrated DNA Technologies (IDT), a...Read more


Arcutis Biotherapeutics: New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice

May 15
Last Trade: 14.22 0.46 3.34

Arcutis convened the Genital Psoriasis Wellness Consortium, a multidisciplinary group of clinicians who are experts in their fields Publication includes 14 consensus statements aimed at improving diagnosis, treatment, outcomes, and shared decision-making Genital involvement occurs in approximately two-thirds of the nine million individuals with plaque psoriasis WESTLAKE VILLAGE, Calif., May 15, 2025 (GLOBE NEWSWIRE) --...Read more


Journal of Clinical Nuclear Medicine Publishes Results of Tiziana Life Sciences’ Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 15
Last Trade: 1.51 0.02 1.34

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the publication of a new study in the Journal of ‘Clinical Nuclear Medicine’ demonstrating that intranasal administration of...Read more


Merus Announces the Journal Publication of Petosemtamab Mechanism of Action

May 15
Last Trade: 54.51 2.18 4.17

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced publication on the mechanism of action of petosemtamab, a bispecific antibody targeting Epidermal Growth Factor Receptor (EGFR)...Read more


Voyager Therapeutics Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

May 15
Last Trade: 3.47 0.29 9.12

LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase (ALPL) to transport a novel AAV capsid across the blood-brain barrier (BBB). The article, titled “Highly conserved brain vascular receptor ALPL...Read more


Takeda: The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

May 14
Last Trade: 15.13 0.11 0.73

Data Demonstrated Statistically Significant Improvements in Primary and Secondary Endpoints with Most Subjects Achieving Near Normal Ranges of Wakefulness and Clinically Meaningful Improvements Across the Broad Range of Symptoms Investigated Oveporexton Found to be Generally Safe and Well Tolerated Phase 3 Readout of Oveporexton Anticipated in 2025 OSAKA, Japan & CAMBRIDGE, Mass. / May 14, 2025 / Business Wire / Takeda (TSE:...Read more


Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

May 14
Last Trade: 0.32 0.00 0.00

Challenge Study measured safety, efficacy against infection and symptomatic disease as well as viral shedding Machine learning analyses identified statistically significant correlates of protection and will be incorporated into the development of Vaxart’s second-generation norovirus vaccine candidate, which is being evaluated in a Phase 1 clinical trial SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc....Read more


Smith+Nephew: A comparative sNPWT study of 10,000+ C-sections shows PICO™ sNPWT reduces complications and cuts healthcare costs by $728,000 per 1,000 patients

May 14
Last Trade: 30.69 0.92 3.09

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published comparative study of single-use Negative Pressure Wound Therapy (sNPWT) devices in Caesarean section (C-section) recovery has identified significant benefits for postpartum use of Smith+Nephew’s leading PICO sNPWT technology. Analyzing real-world data from over 10,000 C-section patients treated at different pressure...Read more


enVVeno Medical: Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

May 13
Last Trade: 4.28 0.32 8.08

Promising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe and effective--achieving a high rate of patency, restoring deep venous competence and maintaining clinical benefits Company has submitted PMA application for the VenoValve to the U.S. Food and Drug Administration (FDA) with a decision anticipated in the second half of 2025 IRVINE, CA / ACCESS Newswire /...Read more


MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

May 13
Last Trade: 20.69 1.31 6.76

Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL® YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is based on data from the...Read more


New Retrospective Study Reports Significantly Reduced Post-Operative GERD Rates with the Titan SGS™ Stapler from Teleflex Compared with Multi-Fire Staplers in Sleeve Gastrectomy

May 13
Last Trade: 118.93 -0.73 -0.61

Data also demonstrate significantly lower rates of postoperative reflux and decreased incidence of de novo gastroesophageal reflux disease (GERD) without affecting total weight loss at 1-year*, and shorter average hospital length of stay (LOS) associated with use of the Titan SGS™ Stapler compared with multi-fire staplers1 WAYNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of...Read more


BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test

May 12
Last Trade: 0.33 -0.01 -2.94

Study Published in a special issue of International Journal of Molecular Sciences Confirms Test's Ability to Distinguish Early Lung Cancer from Other Non-Cancerous Lung Diseases Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, today announced the publication of a pivotal study...Read more


Eli Lilly: Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine

May 11
Last Trade: 786.92 9.26 1.19

Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and waist circumference reduction INDIANAPOLIS, May 11, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound...Read more


Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

May 9
Last Trade: 51.13 0.76 1.51

Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025 SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases...Read more


PureTech Health Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

May 9
Last Trade: 18.30 0.22 1.22

Research conducted in collaboration with IPF experts and the Pulmonary Fibrosis Foundation reveals critical gaps in diagnosis, treatment, and quality of life for people living with IPF Findings highlight the profound physical, emotional, and psychosocial burden of IPF and underscore urgent need for enhanced education, streamlined diagnosis, patient-focused treatment plans, and more effective therapies BOSTON / May 09, 2025 / Business...Read more


Dario's Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations

May 8
Last Trade: 0.71 0.01 1.50

New data, published in JMIR, demonstrates the value of personalized messaging encouraging flu vaccinations in Dario members with diabetes NEW YORK, May 8, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research published in the Journal of Medical Internet Research ("JMIR") demonstrating the effectiveness of personalized digital...Read more


Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

May 7
Last Trade: 5.72 0.18 3.25

SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) --  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world study suggesting that the results of RiskScore® led clinicians to recommend breast cancer screening aligned with patients’ individual risk. RiskScore, Myriad’s clinically validated breast cancer risk assessment...Read more


Telix Pharmaceuticals FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

May 7
Last Trade: 16.92 1.27 8.12

MELBOURNE, Australia and INDIANAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in Thyroid, the official journal of the American Thyroid Association. The candidate demonstrated an encouraging safety profile and efficacy in aggressive, radioiodine-resistant...Read more


Syndax Pharmaceuticals Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

May 7
Last Trade: 9.24 0.49 5.60

Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial  Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate  sNDA for revumenib in R/R mNPM1 AML submitted in April 2025  NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative...Read more


Arcutis Biotherapeutics Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

May 7
Last Trade: 14.22 0.46 3.34

Once-daily, investigational ZORYVE foam 0.3%, rapidly improved psoriasis of the scalp and body, including itch, when used as a monotherapy 66.4% of individuals treated with ZORYVE foam achieved Scalp-Investigator Global Assessment (S-IGA) Success at Week 8 45.5% of individuals treated with ZORYVE foam achieved Body-Investigator Global Assessment (B-IGA) Success at Week 8 Efficacy and safety results were consistent with Phase 2...Read more


NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

May 7
Last Trade: 21.64 1.61 8.04

Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) Phase 3 data showed that obicetrapib as an adjunct to statins, whether in combination with ezetimibe or as monotherapy, reduced LDL-C by 50% and 35%, respectively; in addition, Phase 2 data of obicetrapib in combination with moderate-dose statins showed LDL-C reductions of...Read more


Natera: Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

May 7
Last Trade: 161.75 3.27 2.06

Study published in American Journal of Transplantation highlights strong sensitivity and specificity, along with a >37% reduction in false positives when using Prospera Heart with DQS Adds to the growing body of evidence supporting DQS for dd-cfDNA analysis in solid organ transplant AUSTIN, Texas / May 07, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced...Read more


IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

May 6
Last Trade: 0.71 -0.02 -2.66

Data from OVATION 2 trial will also be reviewed in an oral presentation at ASCO Annual Meeting on June 3, 2025 LAWRENCEVILLE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that data from the company’s Phase 1/2 OVATION 2 trial evaluating intraperitoneal IMNN-001 in combination with neoadjuvant and adjuvant...Read more


MiMedx Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)

May 5
Last Trade: 6.96 -0.04 -0.57

MARIETTA, Ga., May 05, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of its health economics data for reconstruction of cutaneous wounds with EPIFIX® (Dehydrated Human Amnion Chorion Membrane, or DHACM) following Mohs surgery. The study has been published in the May 2025 issue of Journal of Drugs in Dermatology: “Placental allograft reconstruction of cutaneous wounds...Read more


Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology

May 1
Last Trade: 6.77 0.36 5.62

BOSTON / May 01, 2025 / Business Wire / Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that results from a Phase 1a trial in healthy subjects supporting navenibart’s potential to provide long-acting, safe, and effective attack prevention for hereditary angioedema (HAE) with dosing every 3 and 6 months have been...Read more


Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia

May 1
Last Trade: 0.02 0.00 0.00

HALIFAX, Nova Scotia, May 01, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia, a potentially lethal bacterial infection. Dr. Carl Gelhaus, Ph.D., Director of...Read more


New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

April 30
Last Trade: 20.12 0.36 1.82

Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to forgo sentinel lymph node biopsy (SLNB) surgery FRIENDSWOOD, Texas, April 30, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced...Read more


Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

April 29
Last Trade: 81.50 2.70 3.43

CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the publication of a manuscript in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research, which supports the rational molecular design of zidesamtinib, its...Read more


Tempus AI Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection

April 29
Last Trade: 58.41 -0.10 -0.17

The validation study recently published in the Journal of Molecular Diagnostics CHICAGO / Apr 29, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy” in the Journal of Molecular Diagnostics. Data from this study...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE